Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli

Oren Zimhony, Catherine Vilchèze, Masayoshi Arai, John T. Welch, William R. Jacobs

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

The activity of different analogs of pyrazinamide on Mycobacterium tuberculosis fatty acid synthase type I (FASI) in replicating bacilli was studied. Palmitic acid biosynthesis was diminished by 96% in bacilli treated with n-propyl pyrazinoate, 94% in bacilli treated with 5-chloro-pyrazinamide, and 97% in bacilli treated with pyrazinoic acid, the pharmacologically active agent of pyrazinamide. We conclude that the minimal structure of pyrazine ring with an acyl group is sufficient for FASI inhibition and antimycobacterial activity.

Original languageEnglish (US)
Pages (from-to)752-754
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume51
Issue number2
DOIs
StatePublished - Feb 1 2007

Fingerprint

Type I Fatty Acid Synthase
Pyrazinamide
Bacillus
Esters
Pyrazines
Palmitic Acid
Mycobacterium tuberculosis
pyrazinoic acid

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. / Zimhony, Oren; Vilchèze, Catherine; Arai, Masayoshi; Welch, John T.; Jacobs, William R.

In: Antimicrobial Agents and Chemotherapy, Vol. 51, No. 2, 01.02.2007, p. 752-754.

Research output: Contribution to journalArticle

@article{84f067ab9eab4a148a7837d6f80db648,
title = "Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli",
abstract = "The activity of different analogs of pyrazinamide on Mycobacterium tuberculosis fatty acid synthase type I (FASI) in replicating bacilli was studied. Palmitic acid biosynthesis was diminished by 96{\%} in bacilli treated with n-propyl pyrazinoate, 94{\%} in bacilli treated with 5-chloro-pyrazinamide, and 97{\%} in bacilli treated with pyrazinoic acid, the pharmacologically active agent of pyrazinamide. We conclude that the minimal structure of pyrazine ring with an acyl group is sufficient for FASI inhibition and antimycobacterial activity.",
author = "Oren Zimhony and Catherine Vilch{\`e}ze and Masayoshi Arai and Welch, {John T.} and Jacobs, {William R.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1128/AAC.01369-06",
language = "English (US)",
volume = "51",
pages = "752--754",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli

AU - Zimhony, Oren

AU - Vilchèze, Catherine

AU - Arai, Masayoshi

AU - Welch, John T.

AU - Jacobs, William R.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - The activity of different analogs of pyrazinamide on Mycobacterium tuberculosis fatty acid synthase type I (FASI) in replicating bacilli was studied. Palmitic acid biosynthesis was diminished by 96% in bacilli treated with n-propyl pyrazinoate, 94% in bacilli treated with 5-chloro-pyrazinamide, and 97% in bacilli treated with pyrazinoic acid, the pharmacologically active agent of pyrazinamide. We conclude that the minimal structure of pyrazine ring with an acyl group is sufficient for FASI inhibition and antimycobacterial activity.

AB - The activity of different analogs of pyrazinamide on Mycobacterium tuberculosis fatty acid synthase type I (FASI) in replicating bacilli was studied. Palmitic acid biosynthesis was diminished by 96% in bacilli treated with n-propyl pyrazinoate, 94% in bacilli treated with 5-chloro-pyrazinamide, and 97% in bacilli treated with pyrazinoic acid, the pharmacologically active agent of pyrazinamide. We conclude that the minimal structure of pyrazine ring with an acyl group is sufficient for FASI inhibition and antimycobacterial activity.

UR - http://www.scopus.com/inward/record.url?scp=33846605483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846605483&partnerID=8YFLogxK

U2 - 10.1128/AAC.01369-06

DO - 10.1128/AAC.01369-06

M3 - Article

C2 - 17101678

AN - SCOPUS:33846605483

VL - 51

SP - 752

EP - 754

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -